Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event - Additional Information (Detail)

v3.10.0.1
Subsequent Event - Additional Information (Detail)
9 Months Ended
Nov. 09, 2018
USD ($)
Day
$ / shares
shares
Oct. 08, 2018
shares
May 14, 2018
shares
Sep. 30, 2018
USD ($)
shares
Oct. 26, 2018
USD ($)
Subsequent Event [Line Items]          
Borrowings under lines of credit       $ 3,323,000  
Repayments of lines of credit       $ 1,823,000  
Restricted Stock Units (RSUs)          
Subsequent Event [Line Items]          
Granted | shares       2,747,000  
Restricted Stock Units (RSUs) | Board Members          
Subsequent Event [Line Items]          
Granted | shares     398,275    
Options vesting description       398,275 shares to certain Board members of the Company. These awards were valued at $1.45 per share, the closing price of BIOLASE common stock on the grant date, and fully vest on the first anniversary of the grant date  
Subsequent Event | SWK Warrants          
Subsequent Event [Line Items]          
Warrants issued to purchase shares of common stock | shares 372,023        
Warrants expire date Nov. 09, 2026        
Initial exercise price of warrants | $ / shares $ 1.34        
Number of trading days of average closing price of common stock | Day 10        
Subsequent Event | Western Alliance          
Subsequent Event [Line Items]          
Repayments of lines of credit $ 900,000        
Subsequent Event | SWK Loan          
Subsequent Event [Line Items]          
Line of credit facility term 5 years        
Borrowings under lines of credit $ 12,500,000        
Line of credit facility maturity date Nov. 09, 2023        
Subsequent Event | SWK Loan | LIBOR          
Subsequent Event [Line Items]          
Line of credit facility interest rate description LIBOR plus 10%        
Line of credit facility bearing floating interest rate per annum 10.00%        
Subsequent Event | Business Financing Agreement | Western Alliance          
Subsequent Event [Line Items]          
Line of credit facility minimum unrestricted cash covenant         $ 300,000
Repayments of lines of credit $ 900,000        
Subsequent Event | Restricted Stock Units (RSUs) | Board Members          
Subsequent Event [Line Items]          
Granted | shares   44,374      
Award vesting date   May 09, 2019      
Options vesting description   Upon her election to the Board and her appointment to the Compensation Committee and Nominating and Corporate Governance Committees of the Board, Dr. Wagner received an automatic award of 44,374 stock-settled RSUs, which fully vest on May 9, 2019. Upon vesting, each unit shall be settled with one share of BIOLASE common stock.